

Visiting Professors

A case-based discussion on the management of breast cancer

Select Publications

A multicenter phase III randomized trial of adjuvant therapy for patients with HER2-positive node-positive or high risk node-negative breast cancer comparing chemotherapy plus trastuzumab with chemotherapy plus trastuzumab plus bevacizumab. **NCT00625898**

A Phase III, multicenter, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastatic breast cancer. **NCT00281697**

A Phase III, randomized clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone receptor-positive and Her2-negative breast cancer with recurrence score (RS) of 25 or less. **NCT01272037**

Bashir MO, Wu S. **Docetaxel-induced neutropenia and neutropenic fever in general and elderly patient population: A meta-analysis.** *Proc ASCO* 2011;Abstract e19729.

Blackwell KL et al. **Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.** *J Clin Oncol* 2010;28(7):1124-30. **Abstract**

Burris HA 3rd et al. **Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.** *J Clin Oncol* 2011;29(4):398-405. **Abstract**

Cardoso F et al. **Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.** *Ann Oncol* 2011;22(Suppl 6):vi25-30. **Abstract**

Gray R et al. **Independent review of E2100: A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.** *J Clin Oncol* 2009;27(30):4966-72. **Abstract**

Hayes DF. **Steady progress against HER2-positive breast cancer.** *N Engl J Med* 2011;365(14):1336-8. **Abstract**

Hirsh RL, Fox KR. **HER2 blockade: Is combination therapy better than monotherapy?** *Curr Treat Options Oncol* 2010;11(3-4):63-5. **Abstract**

Isakoff SJ, Baselga J. **Trastuzumab-DM1: Building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer.** *J Clin Oncol* 2011;29(4):351-4. **Abstract**

Leonard R et al. **Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: A retrospective review of capecitabine for metastatic breast cancer.** *Clin Breast Cancer* 2011;11(6):349-56. **Abstract**

Moelans CB et al. **Validation of a fully automated HER2 staining kit in breast cancer.** *Cell Oncol* 2010;32(1-2):149-55. **Abstract**

Neo ALTT0 (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study: A randomised, multicenter open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer. **NCT00553358**

Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx trial. **NCT00310180**

Slamon D et al. **Adjuvant trastuzumab in HER2-positive breast cancer.** *N Engl J Med* 2011;365(14):1273-83. **Abstract**
Treatment decision impact of Oncotype DX™ in HR+, N- breast cancer patients. NCT01446185

Vishnu P, Roy V. **Safety and efficacy of nab-paclitaxel in the treatment of patients with breast cancer.** *Breast Cancer (Auckl)* 2011;5:53-65. **Abstract**